A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a
in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this
study are to determine (i) the safety and tolerability of interferon beta-1a in participants
with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the
Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.